1-8 of 8
Eduardo Rios-Herranz, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Pau Abrisqueta, MD PhD, Eva González-Barca, MD PhD, Christelle M Ferra, Eduardo Ríos Herranz, MD, Margarita Fernandez, MD, Julio Delgado, MD, Rafael Andreu, MD, Jose Angel Hernandez-Rivas, MD PhD, Maria Jose Terol, Marcos González, Patricia Baltasar Tello, MD, Javier de la Serna, MD PhD, Angel Ramirez Payer, Carmen Ballester, MD, Carol Moreno, MD PhD, Jose A. Garcia-Marco, MD PhD, Raul Cordoba, MD PhD, Lucrecia Yanez San Segundo, MD PhD, Luis Felipe Casado Montero, MD, Francesc Bosch, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4296.
https://doi.org/10.1182/blood-2019-128470
Published: 2019
Journal Articles

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Carmen Martinez, MD PhD, Cecilia Carpio, MD, Inmaculada Heras, Eduardo Ríos Herranz, MD, Joan Buch, Antonio Gutierrez, MD PhD, Samuel Romero, Izaskun Ceberio, Irene Garcia-Garcia, Antonia Rodriguez Izquierdo, PhD, Rosalia Alonso, Joan Bargay, MD PhD, Cristina Barrenetxea Lekue, PhD, Narvaez Javier, Manuel Espeso de Haro, MD, Luis Palomera, MD PhD, Ramon García-Sanz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2936.
https://doi.org/10.1182/blood-2018-99-115774
Published: 2018
Journal Articles

Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jose Garcia-Marco, MD PhD, Patricia Baltasar Tello, Esther González Garcia, Dra., Eduardo Ríos Herranz, MD, Angel Ramirez Payer, María José Terol Castera, Diana Champ, Angeles Medina Perez, Mercedes Gironella, Alicia Rodríguez Fernández, Ana Muntañola Prat, Alexia Suárez Cabrera, Manuel Jurado Chacón, Miguel Fernández Zarzoso, Mercedes Rodríguez, Juana Clavel, Maria Victoria Dourdil Sahun, Christelle M Ferra Coll, Ernesto Pérez Persona, Carmen Milagros Marrero Santos, Rafael Forés, Julio Delgado, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4321.
https://doi.org/10.1182/blood.V130.Suppl_1.4321.4321
Published: 2017
Journal Articles

Clinical, Genomic Profile and Recurrent Somatic Mutations in 205 Chronic Lymphocytic Leukemia Treatment-Naive Patients

Blanca Ferrer, MD, Alicia Serrano, Victoria Adam, Blanca Navarro, MDPhD, Carmen Ivorra, PhD, Angeles Medina, MD, Margarita Fernandez, MD, Alicia Rodriguez, MD, Vanesa Martin, MD PhD, Maria Soledad Duran, MD, Eduardo Ríos Herranz, MD, Carmen Benet, MD, Maria Angeles Ruiz, MD, Mario Montagud, MD, Isabel Navarro, MD, Miguel Fernandez, MD, Ana Isabel Teruel, MD, Macarena Ortiz, MD, Rafael Andreu, MD, Paula Amat, MDPhD, Carlos Solano, MD PhD, Javier F Chaves, PhD, Maria Jose Terol, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1715.
https://doi.org/10.1182/blood.V130.Suppl_1.1715.1715
Published: 2017
Journal Articles

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Ana Marin-Niebla, MD, Monica Else, MA, MSc, Fatima De la Cruz, MD, Paul Batty, MD, Eduardo Rios-Herranz, MD, Claire E. Dearden, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez Simón, MD, PhD, Daniel Catovsky, MD, Estella Matutes
Journal: Blood
Blood (2011) 118 (21): 4986.
https://doi.org/10.1182/blood.V118.21.4986.4986
Published: 2011
Journal Articles

Low-Intensity Fludarabine, Cyclophosphamyde, Rituximab (FCR) as Front-Line Treatment for Follicular Lymphoma. Efficacy and Toxicity Profile of the Oral Versus Intravenous Administration.

Ana Marin-Niebla, MD, Eduardo Rios-Herranz, MD, Fáatima de la Cruz Vicente, Jr., MD, Paula Cerezuela, MD, Jose Francisco Falantes, MD, Mariluz Martino, MD, Ildefonso Espigado, Alvaro Urbano Ispizua, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2690.
https://doi.org/10.1182/blood.V114.22.2690.2690
Published: 2009
Journal Articles

Incidence of Neutropenia and Hypogammaglobulinemia and Correlation with the Infections Rate in Indolent Non-Hodgkin Lymphoma (NHL) Receiving Rituximab Maintenance.

Ana Marin-Niebla, MD, Eduardo Rios-Herranz, MD, Jose F. Falantes, MD, Mariluz Martino, MD, Ildefonso Espigado, MD PhD, Alvaro Urbano-Ispizua, MD PhD
Journal: Blood
Blood (2007) 110 (11): 4495.
https://doi.org/10.1182/blood.V110.11.4495.4495
Published: 2007
Journal Articles

Efficacy and Safety of Fludarabine/Cyclophosphamide (FC) as Front-Line Treatment of CLL. Final Results of a Phase II Clinical Trial in a Single Center.

Ana Marin-Niebla, MD, Eduardo Rios-Herranz, MD, Juan M. Rodriguez, PhD, Ramiro Nunez, MD, Ascension Herrera, MD, Ricardo Parody, MD, Ildefonso Espigado, PhD.
Journal: Blood
Blood (2004) 104 (11): 4826.
https://doi.org/10.1182/blood.V104.11.4826.4826
Published: 2004